Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc. SPRO

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare,...


Recent & Breaking News (NDAQ:SPRO)

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

GlobeNewswire 4 days ago

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

GlobeNewswire 10 days ago

Spero Therapeutics to Present at Upcoming Investor Conference

GlobeNewswire September 7, 2022

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

GlobeNewswire September 6, 2022

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

GlobeNewswire August 10, 2022

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

GlobeNewswire August 9, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 25, 2022 in Spero Lawsuit - SPRO

Newsfile July 25, 2022

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

PR Newswire July 25, 2022

SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRO

Newsfile July 25, 2022

Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate

Business Wire July 25, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

PR Newswire July 25, 2022

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 25, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022

PR Newswire July 25, 2022

Spero Class Action: Levi & Korsinsky Reminds Spero Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 25, 2022 - SPRO

Newsfile July 22, 2022

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Business Wire July 22, 2022

SPRO FINAL DEADLINE ALERT: TOP RANKED ROSEN LAW FIRM Encourages Spero Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRO

Newsfile July 22, 2022

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 22, 2022

SPRO SHAREHOLDER ALERT: Jakubowitz Law Reminds Spero Shareholders of a Lead Plaintiff Deadline of July 25, 2022

PR Newswire July 22, 2022

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers - SPRO

PR Newswire July 21, 2022

SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire July 21, 2022